Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by pool1212on Aug 22, 2012 7:05am

195 Views

Post# 20245186

clinical trials - iDEAL study details link

for anyone who wishes to understand more information as to the iDeal study, including definitions associated with different phases and terminology used in the clinical trials, the following link provides a good deal if information. In addition there are numerous links to FDA processes etc.

https://clinicaltrials.gov/ct2/show/NCT01565148

please note, this site provides information about a trial's purpose, those who may participate, where can a participant participate etc and is not meant as a sales tool

regards

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario